Purchase Order HHSN271201300039P

This contract award to Gempharmatech LLC, a foreign-owned biotechnology company in San Diego, California, is for a $58,936 fixed-price purchase order to evaluate the safety of the compound YC1 in mice with humanized SULT1A1 proteins versus standard mouse SULT1A1 proteins. The contract was awarded by the National Center for Advancing Translational Sciences (NCATS), which operates under the National Institutes of Health within the Department of Health and Human Services. The objective is to...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $108,000 purchase order to Pharmaron, Inc. for pharmacokinetics experiments involving forty rodents across two study arms. The one-year contract has Pharmaron performing the work in China under a firm fixed price arrangement. No additional details were provided on subcontractors or the specific NIH programs the research aims to support. The award information...

This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $113,400 contract is part of the NIH Bioanalysis Testing Services 2015-2020 IDIQ (Indefinite Delivery/Indefinite Quantity) vehicle. The work involves conducting pharmacokinetic assessments, toxicity studies, and ion channel testing services to support drug discovery and development efforts, including evaluating...

This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services. The $10,656.00 contract is for a pharmacokinetic (PK) study in mice, with a final completion date of September 21, 2026. The work will be performed at Pharmaron's division in Louisville, Kentucky....

This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...

This is a firm fixed-price delivery order award to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services for pharmaceutical and biotechnology companies, as well as government agencies. The $9,180 award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH). The work will be performed in Louisville, KY and is related to the NIH Bioanalysis Testing Services 2015-2020...

This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...

This firm fixed-price purchase order contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Pharmaron, Inc., a minority-owned for-profit contract research organization, to conduct Good Laboratory Practice (GLP) toxicity studies in rats and dogs. The $102,250.00 contract supports the Institute's Investigational New Drug (IND) enablement project, with Pharmaron performing services such as...

The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $39,060 firm fixed price purchase order to Pharmaron, Inc. to evaluate absorption, distribution, metabolism, and excretion of compounds from an NIH dystonia research project. Per the sole source solicitation, Pharmaron will leverage its unique experience with the class of compounds to provide consistency and reproducibility in the evaluation process, compare new analogs to previous ones in the same...

This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...